inhibitor

(redirected from reverse transcriptase inhibitor)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Encyclopedia, Wikipedia.
Related to reverse transcriptase inhibitor: NNRTI, NRTI
See: deterrent
References in periodicals archive ?
Merck also intends to commence with a Phase II study of MK-1439, an investigational next generation non-nucleoside reverse transcriptase inhibitor.
Other factors associated with severe hepatotoxicity in this study were use of nevirapine-containing drugs, which were associated in those taking a non-nucleoside reverse transcriptase inhibitor with both early (OR 4.
based in Research Triangle Park, NC, for CMX157, an investigational oral nucleoside reverse transcriptase inhibitor currently in Phase I clinical development.
Adults: The recommended dosage of SUSTIVA is 600 mg orally, once daily, in combination with a protease inhibitor and/or nucleoside analogue reverse transcriptase inhibitors (NRTIs).
Have failed at least 2 protease inhibitors or 1 protease inhibitor and a non-nucleoside reverse transcriptase inhibitor (i.
Tenofovir, Gilead Sciences' candidate reverse transcriptase inhibitor, could be approved in about six months.
They then added nevirapine (Viramune) and at least 1 nucleoside reverse transcriptase inhibitor (NRTI).
Patients must also have failed treatment with at least two protease inhibitors (PIs) or one PI and one non nucleoside analog reverse transcriptase inhibitor.
Yesterday, October 31, 00, FDA approved a new formulation of the nucleoside reverse transcriptase inhibitor, ddI, called VIDEX EC.

Full browser ?